Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA accepts sNDA for Xeljanz for the treatment of adult patients with active ulcerative colitis

cphi-onlineJuly 17, 2017

Tag: sNDA , active ulcerative colitis

PharmaSources Customer Service